News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biovail Corporation (BVF) Receives Approval Letter From FDA For Tramadol ODT; Oral Disintegrating Tablet Version To Provide Treatment Option For Those Who Suffer From Moderate To Moderately Severe Pain


10/19/2005 5:10:27 PM

TORONTO--(BUSINESS WIRE)--May 6, 2005--Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that it has received an Approval Letter from the United States Food & Drug Administration (FDA) for Tramadol ODT (tramadol hydrochloride), an orally disintegrating tablet version of the analgesic medication tramadol hydrochloride in 50mg dosage format, intended for the treatment of moderate to moderately severe pain in adults. In March, Biovail filed a Complete Response to address routine matters raised in the Approvable Letter received from the FDA in early January. More specifically, these matters involved the resolution of labeling issues only, including, but not limited to, resolution of final packaging, content and format for the product's blister card and carton.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES